American Century Investments Sells Regeneron Pharmaceuticals (REGN) Stake, Citing Disappointment with Commercialization Progress
American Century Investments Focused Dynamic Growth Fund stated in its Q2 2026 investor letter that it had sold its holdings in biotechnology company Regeneron Pharmaceuticals (NASDAQ:REGN). The fund noted that it was disappointed with the slow commercialization progress of Regeneron's macular degeneration treatment and believed its stock had limited appreciation potential, thus choosing to reallocate capital to other more attractive investments.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
MOOLAH Coin: A BEP20 Token on BNB Chain and Its Trading Guide
-
2
1SWAP Token: Project Status, Historical Review, and Market Analysis
-
3
KENSHI (KNS) Analysis: Web3 Data Platform and Its Trading Status
-
4
IMMO Coin Analysis: What is ImmortalDAO Finance (IMMO) and Where to Trade It
-
5
XRP Latest Price Trends and RMB-Denominated Analysis
-
6
Mainstream Decentralized Exchanges and Apps Overview
-
7
Ethereum Validator Queue Dynamics: Why Does Staking Inflow Still Exceed 1.3 Million ETH After Exit Queue Clears?
-
8
WEGLD Token: The Wrapped Token in the MultiversX Ecosystem and Investment Considerations
-
9
U.S. spot Bitcoin ETFs record $773.43 million in two-day net outflows, with BTC price testing $80,000
-
10
Complete Guide to Secure and Fast Transfers Between Trust Wallet and BNB Smart Chain (BSC)
Markets Today
Recommended Reading











